# Astellas Pharma Global Development, Inc. trials: 207 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 207 trials with Astellas Pharma Global Development, Inc. as lead sponsor, 22 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Astellas Pharma Global Development, Inc.: 207 rows for $10.35, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/astellas-pharma-global-development-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 207
- Recruiting or not yet: 22
- Read on: November 19, 2026

## Trials

The 25 newest of 207, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| September 21, 2026 | NCT07829757 | A Study of Zolbetuximab Given With mFOLFOX6 or CAPOX Chemotherapy in Indian Adults With Gastric Cancer | Astellas Pharma Global Development, Inc. | Phase 4 | Not yet recruiting | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07829757) |
| August 24, 2026 | NCT07783282 | A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer | Astellas Pharma Global Development, Inc. | Phase 1 | Recruiting | Prostate Cancer | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783282) |
| August 19, 2026 | NCT07773129 | A Study to Learn How ASP3082 is Processed in Healthy Men | Astellas Pharma Global Development, Inc. | Phase 1 | Completed | Healthy Volunteer | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07773129) |
| August 18, 2026 | NCT07770685 | A Study About the Safety of ASP2767 and Whether it Helps People With Glaucoma-Related Optic Nerve Damage | Astellas Pharma Global Development, Inc. | Phase 1/2 | Recruiting | Glaucoma | 156 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770685) |
| July 28, 2026 | NCT07730021 | A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors | Astellas Pharma Global Development, Inc. | Phase 1/2 | Recruiting | Locally Advanced or Metastatic Solid Tumors | 392 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07730021) |
| June 29, 2026 | NCT07673887 | A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer | Astellas Pharma Global Development, Inc. | Phase 3 | Recruiting | Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma | 570 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673887) |
| May 4, 2026 | NCT07566156 | Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer... | Astellas Pharma Global Development, Inc. | Phase 3 | Recruiting | Urothelial Cancer, Urinary Bladder Neoplasms | 390 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566156) |
| May 4, 2026 | NCT07566052 | A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation | Astellas Pharma Global Development, Inc. | Phase 3 | Recruiting | Non-small Cell Lung Cancer (NSCLC) | 356 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07566052) |
| March 23, 2026 | NCT07488676 | A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors | Astellas Pharma Global Development, Inc. | Phase 1/2 | Recruiting | Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07488676) |
| March 17, 2026 | NCT07475806 | A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder | Astellas Pharma Global Development, Inc. | Phase 2 | Recruiting | Muscle-invasive Bladder Cancer | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07475806) |
| February 23, 2026 | NCT07425574 | A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults | Astellas Pharma Global Development, Inc. | Observational | Recruiting | Stargardt Disease, Stargardt Macular Dystrophy, Stargardt-like Macular Dystrophy | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07425574) |
| February 13, 2026 | NCT07409272 | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With... | Astellas Pharma Global Development, Inc. | Phase 3 | Recruiting | Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma | 614 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07409272) |
| February 9, 2026 | NCT07395024 | A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults | Astellas Pharma Global Development, Inc. | Phase 1 | Active not recruiting | Healthy Volunteer | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07395024) |
| January 14, 2026 | NCT07339267 | A Study to Evaluate the Safety and Drug Levels of ASP5541 in Chinese Participants With Prostate Cancer | Astellas Pharma Global Development, Inc. | Phase 1 | Recruiting | Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07339267) |
| December 17, 2025 | NCT07287995 | A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors | Astellas Pharma Global Development, Inc. | Phase 1/2 | Recruiting | Locally Advanced or Metastatic Malignant Solid Tumors | 428 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07287995) |
| August 24, 2025 | NCT07140016 | A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) | Astellas Pharma Global Development, Inc. | Phase 1 | Recruiting | Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07140016) |
| June 17, 2025 | NCT07024615 | A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer | Astellas Pharma Global Development, Inc. | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07024615) |
| June 5, 2025 | NCT07005154 | A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | Astellas Pharma Global Development, Inc. | Phase 2 | Recruiting | Prostate Cancer, Metastatic Castration-Resistant Prostate Cancer, Metastatic Hormone Sensitive Prostate Cancer | 218 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07005154) |
| March 30, 2025 | NCT06901531 | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer | Astellas Pharma Global Development, Inc. | Phase 3 | Recruiting | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable... | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06901531) |
| March 6, 2025 | NCT06862219 | A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer | Astellas Pharma Global Development, Inc. | Phase 4 | Recruiting | Metastatic Urothelial Carcinoma | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06862219) |
| February 6, 2025 | NCT06812754 | A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Chinese Women Going Through Menopause | Astellas Pharma Global Development, Inc. | Phase 2 | Completed | Hot Flashes | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06812754) |
| January 24, 2025 | NCT06792435 | XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. | Astellas Pharma Global Development, Inc. | Phase 1/2 | Active not recruiting | Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic, Biliary Tract... | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06792435) |
| January 17, 2025 | NCT06779773 | A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy | Astellas Pharma Global Development, Inc. | Observational | Active not recruiting | Geographic Atrophy, Macular Degeneration | 488 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06779773) |
| November 8, 2024 | NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | Astellas Pharma Global Development, Inc. | Phase 1 | Withdrawn | CLDN6-positive Solid Tumor, Ovarian Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Testicular Cancer... | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06681870) |
| August 9, 2024 | NCT06544642 | A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome | Astellas Pharma Global Development, Inc. | Phase 1 | Terminated | Healthy Volunteers, Sjögren's Syndrome | 116 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06544642) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 106 |
| Phase 1/2 | 16 |
| Phase 2 | 34 |
| Phase 3 | 28 |
| Phase 4 | 8 |
| Not applicable | 5 |
| Observational | 10 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 135 |
| Terminated | 24 |
| Recruiting | 21 |
| Active not recruiting | 15 |
| Withdrawn | 6 |
| Approved for marketing | 3 |
| Available | 1 |
| No longer available | 1 |
| Not yet recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasms | 20 |
| Leukemia, Myeloid, Acute | 16 |
| Prostatic Neoplasms | 13 |
| Carcinoma, Non-Small-Cell Lung | 12 |
| Adenocarcinoma | 8 |
| Hot Flashes | 7 |
| Arthritis, Rheumatoid | 7 |
| Carcinoma, Transitional Cell | 6 |
| Neoplasm Metastasis | 6 |
| Stomach Neoplasms | 5 |
| Breast Neoplasms | 4 |
| Urinary Bladder, Overactive | 4 |
| Urinary Bladder Neoplasms | 4 |
| Ovarian Neoplasms | 4 |
| Macular Degeneration | 3 |
| Opioid-Related Disorders | 3 |
| Renal Insufficiency | 3 |
| Pancreatic Neoplasms | 3 |
| Squamous Cell Carcinoma of Head and Neck | 3 |
| Schizophrenia | 3 |
| Melanoma | 2 |
| Stargardt Disease | 2 |
| Geographic Atrophy | 2 |
| Invasive Fungal Infections | 2 |
| Renal Insufficiency, Chronic | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Plastic and reconstructive surgery practices in the United States](https://specstream.ai/data/businesses/plastic-and-reconstructive-surgery-practices/united-states)
- [Electric utilities in the United States](https://specstream.ai/data/businesses/electric-utilities/united-states)
- [Tractor dealers in the United States](https://specstream.ai/data/businesses/tractor-dealers/united-states)
- [Internet service providers in the United States](https://specstream.ai/data/businesses/internet-service-providers/united-states)
- [Banks in the United States](https://specstream.ai/data/businesses/banks/united-states)
- [Pizza restaurants in the United States](https://specstream.ai/data/businesses/pizza-restaurants/united-states)
